Evidence map›Paper›PMID 39767763›Full record

ArticleBiomedicines2024

Immunogenic Cell Death Traits Emitted from Chronic Lymphocytic Leukemia Cells Following Treatment with a Novel Anti-Cancer Agent, SpiD3.

Elizabeth Schmitz, Abigail Ridout, Audrey L Smith, Alexandria P Eiken, Sydney A Skupa, Erin M Drengler, Sarbjit Singh, Sandeep Rana, Amarnath Natarajan, Dalia El-Gamal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. HMGB1: A Central Node in Cancer Therapy Resistance.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Involvement of HMGB1-mediated ferroptosis in systemic diseases.Frontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elizabeth SchmitzEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0002-9619-5193
Abigail RidoutEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Audrey L SmithEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0001-5096-5351
Alexandria P EikenEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0003-0161-7814
Sydney A SkupaEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0002-8933-6015
Erin M DrenglerEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0009-0004-2740-7131
Sarbjit SinghEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0001-5719-967X
Sandeep RanaEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0001-5802-5970
Amarnath NatarajanEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0001-5067-0203
Dalia El-GamalEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0002-1083-8283

Funding

UNMC Structural Biology CoreP20GM103427 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Heather Colleen Jensen-Smith · 2012 to 2026
$59.2M
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI James Eudy · 1985 to 2026
$55.0M
Target Validation CoreP20GM121316 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ADRIAN R BLACK · 2018 to 2026
$23.5M
CHEMICAL CARCINOGENESIS &CANCER BIOLOGYT32CA009476 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Jennifer D. Black · 1988 to 2026
$6.2M
Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven CancersR01CA197999 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Amarnath (Amar) Natarajan · 2016 to 2026
$3.3M
Regulation of extracellular proteases in prostate cancer progression to a metastatic phenotypeR01CA276846 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BERGAN, RAYMOND C., NATARAJAN, AMARNATH (AMAR) · 2023 to 2025
$2.9M
UPR Activators for Cancer TherapyR01CA260749 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Amarnath (Amar) Natarajan · 2022 to 2026
$1.7M
NCI NIH HHS P30 CA036727NCI NIH HHS R01 CA197999NCI NIH HHS R01 CA260749NCI NIH HHS R01 CA276846NCI NIH HHS T32 CA009476NIGMS NIH HHS P20 GM103427NIGMS NIH HHS P20 GM121316NIH HHS CA009476NIH HHS CA197999NIH HHS CA260749NIH HHS CA276846NIH HHS GM103427NIH HHS GM121316UNMC institutional funding, diversity award, and graduate student fellowships
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cancer immunitychronic lymphocytic leukemia (CLL)damage-associated molecular patterns (DAMPs)ferroptosisimmunogenic cell death (ICD)oxidative stressSpiD3

Identifiers

PMID39767763
PMCPMC11673838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.